Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare.
Nicole GormleyLola A Fashoyin-AjeTrevan LockeJoseph M UngerRichard F LittleAjay NookaKhalid MezziMihaela Popa-McKiverRachel KobosYelak BiruTiffany H WilliamsKenneth C AndersonPublished in: Blood cancer discovery (2022)
African Americans are at higher risk of multiple myeloma (MM) yet underrepresented in clinical trials and reap less benefits from novel therapies of the disease. To improve representation of African Americans in MM clinical trials, researchers, providers, patients, industry partners and regulators at the FDA-AACR workshop developed recommendations to all stakeholders. The outlined principles offer a roadmap to addressing disparities broadly in clinical trials.
Keyphrases
- clinical trial
- multiple myeloma
- healthcare
- end stage renal disease
- newly diagnosed
- phase ii
- ejection fraction
- chronic kidney disease
- clinical practice
- peritoneal dialysis
- affordable care act
- open label
- public health
- patient reported outcomes
- phase iii
- study protocol
- double blind
- health insurance
- hepatitis c virus
- antiretroviral therapy
- hiv infected